ASCO 2026: Highlights from Day 2

Osimertinib with/without Chemotherapy in Patients with Persistent ctDNA EGFR Mutant (EGFRm) NSCLC at 3 weeks after 1L Osimertinib: A Randomized Phase II Study (FLAME study)

• In the FLAME phase II study, patients with EGFR‑mutant NSCLC who remained ctDNA‑positive after 3 weeks of first‑line osimertinib derived greater benefit from early addition of chemotherapy versus continuing osimertinib alone, indicating improved disease control with treatment intensification.
• The combination approach resulted in higher response rates and deeper molecular clearance (ctDNA negativity), supporting the use of early on‑treatment ctDNA as a predictive biomarker to identify patients needing escalation.
• The FLAME study explores whether treatment intensification should be dynamically triggered by ctDNA persistence, rather than given to all patients universally.
• Osimertinib plus chemotherapy demonstrated a manageable and expected safety profile, reinforcing the feasibility of a biomarker‑guided, adaptive first‑line treatment strategy.

Reference: LBA101 – ASCO 2026

Low-Dose Pembrolizumab with Chemotherapy in Advanced NSCLC: A Phase 3 Randomized Trial

• Low‑dose pembrolizumab combined with chemotherapy demonstrated comparable efficacy to standard‑dose regimens, achieving similar response rates and disease control outcomes in patients with advanced NSCLC.
• The findings highlight the potential of a reduced‑dose immunotherapy strategy to improve cost‑effectiveness and accessibility without compromising clinical benefit.
• The safety profile of low‑dose pembrolizumab plus chemotherapy remained consistent with established data, with no new safety concerns observed.

Reference: LBA1510 – ASCO 2026

Durvalumab Monotherapy versus Active Monitoring for Resected Primary Renal Cell Carcinoma in RAMPART: An International, Phase 3, Randomized Controlled Trial

• In the RAMPART phase III trial, adjuvant durvalumab did not demonstrate a statistically significant improvement in disease‑free survival compared with active monitoring in patients with resected primary renal cell carcinoma.
• The results suggest limited benefit of single‑agent immune checkpoint inhibition in the adjuvant RCC setting, highlighting the need for better patient selection or combination strategies.
• Durvalumab showed a manageable safety profile consistent with prior studies, but the overall findings do not support routine use of adjuvant monotherapy in this population.

Reference: LBA 4511 – ASCO 2026

Efficacy and Safety of Asandeutertinib versus Osimertinib As First-Line Treatment in EGFR-Mutated NSCLC Patients with Brain Metastases: Interim Analysis of An Open-Label, Multicenter, Randomized, Pivotal Phase II Study (ESAONA)

• In the ESAONA phase II study, asandeutertinib provides superior intracranial objective response rates (iORR) and enhanced CNS efficacy compared with osimertinib as first‑line treatment in EGFR‑mutated NSCLC patients with brain metastases, including improved intracranial and overall response outcomes in the interim analysis.
• Asandeutertinib showed enhanced CNS activity, suggesting a potential advantage in managing patients with baseline brain metastases, a population with high unmet need.
• Safety was manageable and consistent with EGFR TKI class effects, supporting asandeutertinib as a potential alternative first‑line option pending further confirmatory data.

Reference: LBA 2007 – ASCO 2026

Anbenitamab Plus Albumin-Bound Docetaxel (Nab-Docetaxel) ± Carboplatin (Cb) versus Trastuzumab and Pertuzumab Plus Docetaxel (THP) ± Cb as Neoadjuvant Therapy for HER2-Positive Early or Locally Advanced Breast Cancer: A Randomized, Open-Label, Multicenter, Phase 3 Trial

• In this phase III study, anbenitamab‑based neoadjuvant therapy demonstrated improved efficacy compared with standard trastuzumab plus pertuzumab (THP) regimens, with higher pathological complete response (pCR) rates in patients with HER2‑positive early or locally advanced breast cancer.
• The combination of anbenitamab with nab‑docetaxel ± carboplatin showed consistent benefit across subgroups, suggesting a potentially more effective HER2‑targeted neoadjuvant approach.
• The safety profile was manageable and consistent with known toxicities of HER2‑targeted therapy and chemotherapy combinations, supporting its potential as an alternative standard neoadjuvant option.

Reference: LBA 660 – ASCO 2026

frontMIND: Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

• The frontMIND study showed significant improvement in progression-free survival with tafasitamab, lenalidomide, and R-CHOP in untreated DLBCL patients.
• This combination therapy could change DLBCL management, addressing the 40% relapse rate seen with R-CHOP alone.
• Tafasitamab targets CD19, enhancing B-cell lysis through apoptosis and immune mechanisms, and synergizes with lenalidomide.
• The safety profile of the combination was consistent with known data, with no new safety concerns identified.

Reference: LBA 7000 – ASCO 2026

TALAPRO-3: Talazoparib (TALA) + Enzalutamide (ENZA) Compared with Placebo (PBO) + ENZA for The Treatment of Patients (pts) with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Harboring Homologous Recombination Repair (HRR) Gene Alterations

• In the phase III TALAPRO‑3 study, the combination of talazoparib plus enzalutamide significantly improved radiographic PFS compared with enzalutamide alone in patients with HRR‑altered mCSPC.
• The benefit was consistent across key HRR subgroups, reinforcing the role of PARP inhibition combined with androgen receptor pathway inhibition as an effective targeted strategy in this biomarker‑defined population.
• The safety profile of talazoparib plus enzalutamide was manageable and aligned with known toxicities of PARP inhibitors and hormonal therapy, supporting its clinical feasibility in the first‑line mCSPC setting. 

Reference: LBA 5007 – ASCO 2026

Phase 3 Clinical Trial of The Combination of Erlotinib Plus Ramucirumab Compared with Osimertinib on Untreated Advanced or Recurrent Non-Small Cell Lung Cancer with EGFR L858R Mutation: The REVOL858R trial (WJOG14420L)

• While a prior landmark trial (RELAY) established that adding ramucirumab to erlotinib significantly improved PFS compared to erlotinib alone, the REVOL858R study specifically focused on whether this combination could beat osimertinib, the current gold standard. 
• In the phase III REVOL858R trial, erlotinib plus ramucirumab did not demonstrate superiority over osimertinib in untreated advanced NSCLC with EGFR L858R mutation, with efficacy outcomes favoring the current standard of care.
• Osimertinib maintained robust clinical activity, reinforcing its position as the preferred first‑line therapy in EGFR L858R‑mutated disease.
• The safety profile of erlotinib plus ramucirumab was consistent with known toxicities, but without added efficacy benefit, limiting its role compared with osimertinib.

Reference: LBA 8518 – ASCO 2026

Final Results from ZZFIRST: A Randomized Phase 2 Trial of Enzalutamide (EZ) and Talazoparib (TALA) in Metastatic Hormone-Naïve Prostate Cancer (mHNPC)

• In the phase II ZZFIRST trial, the combination of EZ + TALA demonstrated improved clinical activity compared with enzalutamide alone in patients with mHNPC, including enhanced progression‑related outcomes.
• The results support early integration of PARP inhibition with androgen receptor–targeted therapy in selected patients, extending the benefit of combination strategies beyond later‑line settings.
• The safety profile was manageable and consistent with known adverse effects of PARP inhibitors and hormonal therapy, with no unexpected safety signals observed.

Reference: Abs 5006 – ASCO 2026

Integrating BTK Inhibition into R-da-EPOCH for HIV-related DLBCL

• Integration of BTK inhibition into R‑da‑EPOCH showed promising efficacy in patients with HIV‑related DLBCL, with improved response rates and encouraging survival outcomes in this high‑risk population.
• The combination approach supports the biological rationale of targeting B‑cell receptor signaling alongside standard chemoimmunotherapy in virally associated lymphomas.
• The regimen demonstrated a manageable safety profile without significant additive toxicity, indicating feasibility of incorporating BTK inhibitors into frontline treatment for HIV‑associated DLBCL.

Reference: Abs 7001 – ASCO 2026